Doxorubicin liposomal - 2-BBB Medicines

Drug Profile

Doxorubicin liposomal - 2-BBB Medicines

Alternative Names: 2B3-101; 2X-111; Doxorubicin glutathione-pegylated liposome therapeutic - 2-BBB Medicines

Latest Information Update: 27 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator to-BBB technologies
  • Developer 2-BBB Medicines
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action DNA intercalators; DNA topoisomerase III inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Brain metastases; Glioma

Most Recent Events

  • 28 Mar 2017 Oncology Venture plans a phase II trial for Breast Cancer (Metastatic disease) in Denmark
  • 28 Mar 2017 Oncology Venture in-licenses doxorubicin liposomal from 2-BBB
  • 22 Sep 2016 Doxorubicin liposomal - 2-BBB Medicines is available for licensing as of 22 Sep 2016. http://www.2-bbb.com/Partnering
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top